In summary, TNFRSF1A inhibition appears to have a dampening effect on some aspects leucocyte biology and is protective for pneumonia and the autoimmune condition ankylosing spondylitis but conversely displays a risk-increasing relationship with inflammatory-related conditions like Multiple sclerosis, suggesting that more analysis of this candidate therapeutic target is warranted. Here, TNFRSF1A is linked to pneumonia.